Treatment With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (Pcsk9-I) In Clinical Routine – New Data Regarding Familial Hypercholesterolaemia (Fh) Genotype Safety And Efficacy. (August 2019) - Schumann, F.; Hollstein, T.; Steinhagen-Thiessen, E.; Kassner, U.